GAMMA Investing LLC Boosts Stock Position in Moderna, Inc. $MRNA

GAMMA Investing LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 15.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 9,146 shares of the company’s stock after purchasing an additional 1,220 shares during the quarter. GAMMA Investing LLC’s holdings in Moderna were worth $252,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of MRNA. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in Moderna in the first quarter valued at $28,350,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Moderna during the first quarter worth about $28,308,000. Jump Financial LLC grew its holdings in shares of Moderna by 5,590.0% during the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after purchasing an additional 886,567 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after purchasing an additional 877,162 shares during the last quarter. Finally, Sessa Capital IM L.P. purchased a new position in shares of Moderna during the first quarter worth about $21,066,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $24.49 on Friday. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $67.96. The company has a market capitalization of $9.53 billion, a price-to-earnings ratio of -3.25 and a beta of 1.93. The firm has a 50-day simple moving average of $26.91 and a 200-day simple moving average of $27.61.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm’s revenue was down 41.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on MRNA shares. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Leerink Partners dropped their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. Citigroup started coverage on Moderna in a report on Friday, August 1st. They set a “neutral” rating and a $40.00 price objective on the stock. Finally, Barclays dropped their price objective on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.